pentobarbital will lessen the level or outcome of artemether/lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Coadministration with potent CYP3A4 inducers may lead to decreased serum concentrations and loss of antimalarial efficacy
pentobarbital will reduce the level or outcome of theophylline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Clients stabilized on corticosteroid therapy may possibly call for dosage adjustments if barbiturates are added to or withdrawn from their dosage regimen due to induction of hepatic microsomal enzymes by barbiturates
pentobarbital will minimize the level or outcome of bosentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.
If inducer is discontinued, think about oliceridine dosage reduction and check for indications of respiratory despair.
pentobarbital will decrease the level or influence of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Not known.
pentobarbital will lessen the level or influence of sufentanil by influencing get more info hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.
pentobarbital increases toxicity of methoxyflurane by expanding metabolism. Contraindicated. Improved metabolism of methoxyflurane to nephrotoxic compounds.
pentobarbital will minimize the level or effect of sunitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Contraindicated. The therapeutic effect of elbasvir/grazoprevir may be minimized if coadministered with sturdy CYP3A inducers and is also consequently contraindicated.
pentobarbital decreases amounts of elvitegravir/cobicistat/emtricitabine/tenofovir DF by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May well lead to loss of virologic response and doable resistance.
pentobarbital will reduce the extent or effect of osilodrostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the level or outcome of ketoconazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unfamiliar.
Contraindicated (1)pentobarbital decreases amounts of vandetanib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration with powerful CYP3A4 inducers; these drugs lessen publicity to vandetanib by around forty%.